TLDR

• Moderna reported Q4 revenue of $678 million, beating Wall Street estimates of $626.1 million, driven by COVID-19 vaccine sales
• The company posted a quarterly loss of $2.11 per share, narrower than the $2.54 per share loss analysts expected
• Moderna reiterated its 2026 revenue growth target of 10% and expects 50% of sales from U.S. markets and 50% from international
• FDA refused to review Moderna’s flu vaccine application this week, citing trial design f